Active

MPM Capital

Investor type

PE / VC

Founded

1996

AUM

$3 000 M

Location

Boston, Massachusetts, United States

Investment Ticket

$0-1 m

Investment Stage

Seed Series B Series A

Region of investment

North America Europe
Investor profile last updated: 24 April, 2025

Profile

MPM Capital is a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. With its world-class team and deep experience in scientific research, clinical development, and company-building, MPM strives to power novel medical breakthroughs that transform patients’ lives. MPM invests across the biotech landscape with early-stage venture capital funds, and with impact and public equities products through its affiliate BioImpact Capital.

Industry

Life Sciences Healthcare Services Technology MedTech AI Software Medical Devices Biotechnology HealthTech Financial Services Fintech

MPM Capital Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region
Size AUM Launch date
MPM Bio 2014 NVS Strategic Fund
Venture Capital (VC)
Biotechnology
Healthcare Services
Medical Devices
HealthTech
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$54 M
June 2014
MPM BioVentures 2014 LP
Venture Capital (VC)
Biotechnology
Financial Services
Fintech
Healthcare Services
Medical Devices
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$351 M
May 2015
MPM Oncology Impact Fund I
Venture Capital (VC)
Biotechnology
Financial Services
Fintech
Medical Devices
Pre-seed
Seed
Series A
North America
$5-10 m
$471 M
May 2016
MPM Oncology Innovations Fund
Venture Capital (VC)
Biotechnology
Financial Services
Fintech
Healthcare Services
Medical Devices
Pre-seed
Seed
Series A
North America
Europe
$5-10 m
$100 M
February 2019

Contacts

Name
Title
Email
avatar
Tom Barnes Executive Partner
Executive Partner
t•••@•••
avatar
Stephen Curtis Managing Director
Managing Director
s•••@•••
Upgrade to see contacts
avatar
lT50Mrh9I3x1Djnv lT50Mrh9I3x1Djnv
lT50Mrh9I3x1Djnv
avatar
lT50Mrh9I3x1Djnv lT50Mrh9I3x1Djnv
lT50Mrh9I3x1Djnv
avatar
lT50Mrh9I3x1Djnv lT50Mrh9I3x1Djnv
lT50Mrh9I3x1Djnv
Investment-team contacts for MPM Capital — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about MPM Capital

MPM Capital is a venture capital and private equity firm. It backs companies at Seed, Series B and Series A, writing tickets of $0-1 m.
MPM Capital is located in Boston, Massachusetts, United States.
MPM Capital was founded in 1996.
MPM Capital invests in companies and startups in Life Sciences, Healthcare Services, Technology, MedTech, AI, Software, Medical Devices, Biotechnology, HealthTech, Financial Services, Fintech.
MPM Capital invests in companies and startups in North America, Europe.
MPM Capital invests in companies and startups at Seed, Series B, Series A.
MPM Capital usually invests $0-1 m on average.
MPM Capital has around $3 000m assets under management.
MPM Capital last fund was created/launched in 2019-02-27
MPM Capital can be reached through its website mpmbioimpact.com, its LinkedIn page and its X account. Its general enquiries address is info@mpmcapital.com. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for MPM Capital — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query MPM Capital directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 24 April, 2025. Something out of date here? Report it — we re-run that firm within 48h and get back to you.